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Abstract
In humans, mutations in electron transfer flavoprotein (ETF) or electron transfer flavoprotein dehydrogenase (ETFDH) lead to
MADD/glutaric aciduria type II, an autosomal recessively inherited disorder characterized by a broad spectrum of
devastating neurological, systemic and metabolic symptoms. We show that a zebrafish mutant in ETFDH, xavier, and
fibroblast cells from MADD patients demonstrate similar mitochondrial and metabolic abnormalities, including reduced
oxidative phosphorylation, increased aerobic glycolysis, and upregulation of the PPARG-ERK pathway. This metabolic
dysfunction is associated with aberrant neural proliferation in xav, in addition to other neural phenotypes and paralysis.
Strikingly, a PPARG antagonist attenuates aberrant neural proliferation and alleviates paralysis in xav, while PPARG agonists
increase neural proliferation in wild type embryos. These results show that mitochondrial dysfunction, leading to an increase
in aerobic glycolysis, affects neurogenesis through the PPARG-ERK pathway, a potential target for therapeutic intervention.
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Introduction
Mitochondria, the cellular power plants in most eukaryotic
organisms, play pivotal roles in cell signaling, differentiation, and the
control of cell cycle, growth and death. Particularly in the nervous
system, mitochondrial function is essential in meeting the high energy
demand in neuronsand glia[1,2].During nervoussystemdevelopment,
mitochondria regulate neural proliferation and differentiation by
supporting the different bioenergetic requirements of highly prolifer-
ative neural stem cells compared to postmitotic neurons[3]. Mito-
chondrial dysfunction has been implicated in various aspects of
neuronal and glial dysfunction, aging, as well as in the pathogenesis of
neurodegenerative diseases[1,2,4]. However, how mitochondria cause
and compensate for physiological and pathological challenges, and
how this in turn affects neurogenesis, neural development, and nervous
system function, remain poorly understood.
Multiple acyl-CoA dehydrogenase deficiency (MADD), also
known as glutaric aciduria type II, is an autosomal-recessive
inherited disorder caused by mutations in electron transfer
flavoprotein (ETF) or electron transfer flavoprotein dehydrogenase
(ETFDH)[5]. In mitochondria, ETF, located in the matrix, receives
electrons from several dehydrogenases involved in fatty acid
oxidation, choline and amino acid metabolism. ETF then transfers
electrons to ETFDH, located in the inner mitochondrial mem-
brane, and subsequently, electrons are passed to ubiquinone in the
respiratory chain, leading to ATP production[6,7]. As a result of
ETF or ETFDH deficiency, the acyl-CoA dehydrogenases are
unable to transfer the electrons generated by dehydrogenation
reactions, resulting in the accumulation of various intramitochon-
drial acyl-CoA esters. There is secondary accumulation of free
acids, and other conjugation products (acylcarnitine and acylglycine
esters) in blood and urine, including large amounts of the lysine
metabolic intermediate glutaric acid, giving the disease its name[5].
The clinical features of MADD are highly heterogeneous and
have been classified as neonatal-onset form with (type I) or without
(type II) congenital anomalies, and mild and/or late-onset form
(type III). MADD consists of a large spectrum of symptoms,
including hypotonia, hypoglycemia, cardiomyopathy, polycystic
kidneys, and neurological manifestations such as symmetric warty
dysplasia of the cerebral cortex, encephalopathy and leukodystro-
phy. While there have been case studies reporting the use of
riboflavin[8] and sodium-3-hydroxybutyrate[9,10] as treatment
for MADD on a patient-by-patient basis, no systematic therapy
has been validated. Moreover, despite the neurodevelopmental
and cognitive dysfunction prominent in MADD patients, the
anatomical, cellular and molecular abnormalities within the
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mechanisms underlying neural phenotypes remain unexplored.
Here we report the genetic, cellular and molecular characterization
of a zebrafish mutant xav. We had previously identified xav as a mutant
that exhibits abnormal motility and aberrant neuromuscular synapto-
genesis[11]. We found that the xav mutation resides in ETFDH, which
is critical for fatty acid, amino acid and choline metabolism. Because
d y s f u n c t i o no ft h i sg e n ei sr e s p o n s i b l ef o rh u m a nM A D D ,w e
performed several cellular and molecular analyses on xav mutants and
fibroblast cells from MADD patients. Our results advance our
understanding of how metabolism affects neural development, link
mitochondrial dysfunction and the resulting increase in aerobic
glycolysis to neurogenesis via the PPARG-ERK pathway, and suggest
this pathway as a target for therapeutic intervention in human MADD.
Materials and Methods
Ethics Statement
All zebrafish husbandry and experimentation were conducted
under a protocol approved by the University of Pennsylvania’s
Institutional Animal Care and Use Committee. Human fibroblasts
were obtained from patients after written informed consent was
obtained from parents/next of kin, under a protocol approved by the
Institutional Review Board of Children’s Hospital of Wisconsin and
theInstitutionalReview Board ofChildren’sHospital of Philadelphia.
Zebrafish Husbandry
Zebrafish wereraised and maintainedunder standard conditions.
The xav allele was previously described[11]. Wild type and mutant
embryos were obtained from crosses between adult zebrafish.
Fibroblasts from Human MADD Patients
Fibroblasts from a MADD patient 1, were obtained from Dr.
William J. Rhead, Department of Pediatrics, Children’s Hospital
of Wisconsin. Fibroblasts from an age-matched control patient (an
infant, ,1 year of age, with no evident related disease) were
obtained from Dr. Carsten Bonnemann, Children’s Hospital of
Philadelphia. Patient 1 is a deceased newborn with severe MADD,
whose acylcarnitine profile showed elevations of C5- and C16-
intermediates, and extremely low C2-carnitines (Dr. Rhead,
personal communication). We found that patient 1showed mis-
splicing of ETFA transcript, lacking the long isoform that contains
exon2. Gene sequencing showed that patient 1 has a 52 C.T
heterozygous mutation in exon2 that may cause the splicing
defects. The same mutation has been reported in a MADD patient
with neonatal neurological deterioration and metabolic acido-
sis[36]. Fibroblasts from passages 6 – 12 were grown to 80–100%
confluency and used for metabolic or gene expression analyses as
indicated. Fibroblasts were obtained from patients after written
informed consent was obtained from parents/next of kin, under a
protocol approved by the Institutional Review Board of Children’s
Hospital of Wisconsin and the Institutional Review Board of
Children’s Hospital of Philadelphia.
Morpholino Injection
The morpholino antisense oligonucleotide (Gene Tools) target-
ing the etfdh intron2-exon3 junction (CTACCCCTGAAAA-
CATTCAATTATA) was injected at the 1–2 cell stage at ,8 ng.
Plasma Acylcarnitine and Organic Acid Profiling
Sonicated fish (N=40–80) were subjected to acylcarnitine and
organic acid analysis. Acylcarnitines were analyzed by tandem mass
spectrometry as butyl esters using the procedure initially developed
for skin fibroblast acylcarnitine analysis[37]. Organic acids were
analyzed as their trimethylsilyl derivatives by capillary gas chroma-
tography- electron impact mass spectrometry using a procedure that
was initially developed for urine and vitreous humour analysis[38].
RNA Extraction and Quantitative RT-PCR (qRT-PCR)
RNA was extracted from a pool of 20 embryos with the RNeasy
kit(Qiagen). The primers forqRT-PCR areshown inSupplemental
Table S2. qRT-PCR was performed with the SuperScriptH III
PlatinumH SYBRH Green One-Step qPCR Kit w/ROX (Invitro-
gen) and data was analyzed with 7500 Real-Time PCR System
software (Applied Biosystems) using the 2
2DCT method, data were
normalized to b-actin1 for zebrafish and ACTB for fibroblasts.
BrdU Labeling and Immunostaining
BrdU labeling was performed as described previously [39]. In
brief, at ,56–60 hpf, embryos were incubated with 10 mM BrdU
in 10% DMSO in embryo medium for 30 min. on ice and then
raised in embryo medium at 28.5uC for 30 min. The embryos were
then fixed using 4% paraformaldehyde in PBS, pH=7.4, followed
by 2 hour incubation in 2 M HCl. Embryos were anesthetized,
fixed and immunostained as described previously[11] using
antibodies against BrdU (mouse monoclonal Developmental
Studies Hybridoma Bank (DSHB); rabbit polyclonal, Abcam) and
dp-ERK (Sigma) and the appropriate fluorescently conjugated
secondary antibody (Jackson Labs). Unless otherwise stated, each
figure panel showing immunostaining is a single plane projection of
a confocal z-stack of 20–60 1 mm thick planes (Leica TCS 4D
system) and was assessed using interactive software (Metamorph).
Western Blotting
To prepare protein, embryos were triturated in lysis buffer
(100 mM pH 8 Tris, 1% SDS, 10 mM EDTA, 50 mM DTT).
Protein quantity was assessed (Dc Protein Assay; Bio-Rad) and
proteins were separated by SDS-PAGE (4–10% gradient gel),
transferred to a nitrocellulose membrane and probed with
antibodies against AMPKa (Cell Signaling), phospho-AMPKa
(Thr172) (Cell Signaling), PPARG (Santa Cruz), dp-ERK (Sigma),
phospho-STAT3 (Tyr705) (MBL) and/or actin (Sigma). After
washing, blots were incubated in AP-conjugated secondary
antibody (Jackson Labs), and then visualized using chemilumines-
cence (WesternStar detection system; Applied Biosystems).
ROS Labeling
Embryos were incubated in embryo medium containing 10 mM
of dyhydrorhodamine123 (DHR123, Invitrogen) for 2 hrs at
28uC, then washed with embryo medium several times and
examined with confocal microscopy.
PPARG Pharmacology
Embryos were incubated in 25 m m PPARG antagonist
BADGE[28] or agonist 10 mM Ciglitizone[40] at ,24 hpf until
the desired developmental stage.
Statistical Analyses
All statistical analyses were performed with Prism software
(Microcal) and Excel (Microsoft).
Results
External Phenotypes, Genetic Cloning and Morpholino
Phenocopy of xav
We previously identified xav in a small scale genetic screen due
to its abnormal swimming behavior and decreased number of
Zebrafish Model of MADD
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distinguished from WT until after 48 hpf, when they start to
exhibit a bent tail and slower heart beat, phenotypes that become
progressively more severe (Figure 1A, 1B).
Positional cloning strategies (Figure S1; Sup. Table S1) identified
xav mutation resides in zgc:92093, which encodes electron-transfer-
flavoprotein dehydrogenase (etfdh) (Figure 1C). There is a T to A
transversion at position 1305 which introduces a premature stop
codon (Y435X) in the 617 amino acid protein (Figure 1D, 1E).
Besides the truncation of the protein caused by the xav etfdh
mutation, we also found that the overall abundance of etfdh mRNA
in xav is dramatically reduced. Real-time quantitative RT-PCR
(qRT-PCR) showed that there is 80% reduction of etfdh mRNA
(Figure S2A), likely due to nonsense mediated decay[12].
Furthermore, xav mutants showed nonsense mediated alternative
splicing. As a result of the mutation, which resides in exon11, the
exon10-exon13 junctions are mis-spliced in mutants, resulting in
transcripts that are predicted to encode proteins lacking critical
domains or truncated (Figure S2B). These results suggest that xav
contains a likely loss of function mutation in etfdh.
To confirm whether etfdh is the gene mutated in xav, we designed
a splice-blocking morpholino against etfdh and compared the
phenotypes in morphants and mutants. Injection of 8 ng etfdh
MOI2E3 in WT embryos, which targets intron2-exon 3 junction,
results in .80% reduction of the normal transcript at 2 and 3 dpf,
producing a mis-spliced transcript that lacks exon3 (Figure S3C,
3D), resulting in predicted protein fragment lacking all functional
domains (Figure 1E). etfdh morphants not only showed bent tail and
reduced heart beat (Figure 1A, 1B), but also exhibited aberrant
swimming behavior and reduced neuromuscular synaptogenesis
(see Supplemental Results Text S1; Figure S6; and data not shown),
as in xav mutants (Sup. Video S1; Sup. Video S2). These results
indicate that etfdh mutation is responsible for xav phenotypes.
xav Mutants Exhibit Plasma Acylcarnitine and Organic
Acid Profiles Similar to Those in MADD Patients
Given the fact that xav and MADD patients have mutation in
the same gene, we asked whether xav mutants exhibit phenotypes
similar to those seen in human patients. Clinically, MADD is
diagnosed by the plasma acylcarnitine profile, the urine organic
acid profile and acylglycine analysis. These analyses were thus
performed in xav mutants compared to WT embryos.
Tandem mass spectroscopy of plasma acylcarnitine detected a
markedly higher level of a spectrum of intermediate acyl-fatty acid
species in xav mutants, including C4, C5, C6, C8, C14, C16 and
C18, together with a drastic reduction of C2 acylcarnitine
(Figure 2A), suggesting dysregulation of mitochondrial b-oxidation
and alterations in multiple intermediary mitochondrial metabolic
pathways in xav, similar to that observed in MADD patients[5].
Gas chromatographic analysis of organic acids from embryo
homogenates detected a dramatic elevation of glutaric acid in xav
(Figure 2B). Further quantification showed the glutaric acid
content in xav is 0.99 mg/embryo, but ,0.05 mg/embryo in WT,
resembling the glutaric acidemia seen in MADD patients[5].
While acylglycine analysis showed elevated acylglycine levels in
MADD patients, no acylglycine was detected in either WT or xav
embryos. This suggests that the function of glycine-N-acyltransfer-
ase, which converts acyl-CoA and glycine to CoA and acylglycine,
may not be conserved between zebrafish and humans. Moreover,
Figure 1. External phenotype, genotype, cloning and morpholino phenocopy of xav mutants. A. External xav and etfdh morphant (MO)
phenotypes at ,60 hpf include a bent and thinner tail and smaller head and eyes. Scale bar=100 mm. B. xav mutants and MO exhibit slower heart
beat (WT 15866 beats/minute, N=13 embryos; xav 8767; N=14 embryos; MO 6567, N=14 embryos; one-way ANOVA, followed by Dunn’s pairwise
comparison, * p,0.001. C. Genetic and physical map of the xav (zgc:92093) locus (red), including microsatellite and SSR markers, number of
recombinants, and BAC clones from the T51 radiation hybrid panel. D. etfdh mutation in xav is a T to A mutation (blue box) resulting in a premature
stop codon (red box). The amino acid sequence of etfdh is highly conserved among several species, from C. elegans to human. E. Schematic location
of xav mutation, resulting in truncation of the C terminal. etfdh MO is predicted to give rise to a protein fragment lacking all functional domains.
doi:10.1371/journal.pone.0008329.g001
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level in xav mutants compared to WT embryos at ,60 hpf (Figure
S3), consistent with a polycystic kidney phenotype that is
prominent in MADD patients. Together, these analyses show
that the etfdh mutation in xav results in MADD like metabolic and
kidney defects.
xav Mutants Exhibit Several Hallmarks of Mitochondrial
Dysfunction
Given that etfdh functions in mitochondria, and is involved in
electron transport from fatty acid and amino acids, we asked
whether mitochondrial function is abnormal in xav mutants. First,
we evaluated the respiratory and phosphorylation activities in
homogenates of xav mutants and WT embryos at ,56 hpf, by
measuring O2 consumption in the presence of a-ketoglutarate or
fatty acids (palmitoylcarnitine and octoylcarnitine) as substrates
(see Supplemental Experimental Procedures Text S1). ADP-
stimulated (state 3) rates of O2 consumption were decreased
,30–35% in xav mitochondria with each of these substrates
(Figure 3A; Figure S4A). The blunted rates of state 3 respiration in
xav mitochondria (Figure S4A) suggest that oxidative phosphory-
lation is compromised in xav mutants.
Mitochondria establish a transmembrane potential, which is
generated when the energy released by the flow of electrons
through the electron transport chain is used to pump protons out
of the mitochondrial inner membrane through complexes I, III,
and IV, and is utilized to support critical cellular processes, such as
the production of ATP and Ca
2+ uptake. We estimated
mitochondrial membrane potential using the positively charged
fluorescent probe tetramethylrhodamine ethyl ester (TMRE) in xav
mutant and WT embryos at ,56 hpf. Mitochondrial transmem-
brane was estimated as the difference in fluorescence signals
following substrate energization and complete depolarization and
collapse of the membrane potential following addition of
uncoupler. We found a ,50% reduction of membrane potential
generated by oxidation of fatty acid (palmitoylcarnitine and
µ
Figure 2. Xav mutants display abnormal acylcarnitine and organic acid profile. A. Representative acylcarnitine profile from homogenates
of WT and xav mutant embryos using tandem mass spectrometry, showing a markedly higher level of several intermediate acyl-fatty acid species in
xav mutants including C4, C5, C6, C8, C14, C16 and C18, and a reduction of C2 acetylcarnitine (pool of ,100 embryos for xav mutant and WT at
,56 hpf). B. Representative organic acid profile from homogenates of WT and xav mutant embryos using gas chromatography electron impact mass
spectrometric analysis, showing an elevation of the level of glutaric acid in xav mutants (black arrow) (pool of ,100 embryos for xav mutant and WT
at ,56 hpf).
doi:10.1371/journal.pone.0008329.g002
Zebrafish Model of MADD
PLoS ONE | www.plosone.org 4 December 2009 | Volume 4 | Issue 12 | e8329α α
β γ α
α
β
Figure 3. xav mutants exhibit mitochondrial dysfunction. A. Measured rates of state 3 respiration supported by oxidation of a-ketoglutarate
and fatty acids (palmitoylcarnitine and octoylcarnitine (each + malate)) showed a 30–35% reduction in xav mutant compared to WT embryos at
,56 hpf (values normalized to WT; a-ketoglutarate in xav, 0.7260.10; N=4 experiments 50–100 embryos each; Student’s t test, * p=0.03; fatty acid
0.6560.10 in xav; N=4 experiments 50–100 embryos each; Student’s t test, * p=0.02). B. Membrane potential generated by oxidation of a-
ketoglutarate and fatty acids was estimated using TMRE and spectrofluorometry, showing a 55% increase in xav compared to WT at ,56 hpf (values
normalized to WT; a-ketoglutarate xav 1.55 6 0.15; N=4 experiments 50–100 embryos each; Student’s t test, *** p,0.001) and a 50% reduction (fatty
acids xav 0.5360.07; N=5 experiments 50–100 embryos each; Student’s t test, *** p,0.001). C. Measured O2 consumption rates with ascorbate/
TMPD showed a 40% increase in xav compared to WT at ,56 hpf (values normalized to WT; xav 1.3960.13; N=6 experiments 50–100 embryos each;
Student’s t test, * p=0.014). D–E. Western blot showed that while the total level of AMPK is unchanged in xav, the amount of activated AMPK
(phospho-AMPKa
Thr172) protein is significantly increased. Quantification showed a 2.3 fold increase in xav mutants compared to WT embryos (values
normalized to WT; xav 2.360.6; N=3 experiments 30 embryos each; Student’s t test, * p,0.05). F. Levels of ATP production showed a ,45%
reduction in xav mutants compared to WT embryos (WT 20.662.6 nmol per mg protein; xav 11.362.3 nmol per mg protein; N=9 replicates, 50–100
embryos each, Student’s t test, * p,0.05). G. mRNA levels of genes involved in mitochondrial function and biogenesis were analyzed with qRT-PCR. A
,30–40% reduction was observed in mt-nd5 and ndufs1, and a ,2.4, 1.5 and 2.8 fold increase was observed in pgc-1b, esrra and pparc in xav mutants
compared to WT. Expression of zebrafish uncoupling protein 4 (fucp4) was increased ,6 fold, while expression of ucp2 was unchanged (N=3–4
replicates, 20 embryos each; Student’s t test, * p,0.05, ** p,0.01, *** p,0.001). H. The oxidative fluorescent dye DHR-123 was used to measure
cellular superoxide production in live embryos and showed higher cellular superoxide levels in xav mutants compared to WT, especially in the
nervous system, including in the spinal cord. Scale bar=100 mm. I. Expression profile of genes known to be involved in the ROS pathway was assayed
with qRT-PCR and showed a ,50% reduction of catalase transcripts and ,5 fold increase of glutathione reductase and hspa9 in xav compared to WT
(N=3 replicates, 20 embryos each; Student’s t test, * p,0.05, ** p,0.01).
doi:10.1371/journal.pone.0008329.g003
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in state 3 O2 consumption with these substrates. Surprisingly,
however, despite the decrease in the rate of state 3 O2
consumption observed with a-ketoglutarate in xav, mitochondrial
membrane potential was estimated to be increased by ,50%
(Figure 3B). This result suggests that the transmembrane potential
generated when a-ketoglutarate is oxidized by the electron
transport chain may not be properly utilized for ADP phosphor-
ylation in xav mutants.
Despite reduced rates of state 3 O2 consumption observed
following the oxidation of a-ketoglutarate and fatty acid in xav, the
activity of complex IV was increased by 40% when assayed
directly after addition of ascorbate/N,N,N9,N9-tetramethyl-p -
phenylenediamine (TMPD) (Figure 3C), suggesting a possible
compensatory metabolic response to augment respiratory capacity
in xav mutants. Consistent with this idea, at ,56 hpf, a higher
level of F1-F0 ATPase (complex V) protein was detected by
immunostaining in xav mutants compared to WT (Figure S4B).
This likely reflects an adaptation to insufficient respiration, and is
consistent with compensation.
To further assess mitochondrial defects, we examined the
activity of AMP-activated protein kinase (AMPK), which is an
evolutionarily conserved metabolic sensor that responds to
alterations in cellular energy levels to maintain energy balance.
AMPK activation occurs in response to ATP depletion and a
concomitant increase in the AMP/ATP ratio. Once activated,
AMPK phosphorylates numerous downstream substrates thereby
initiating a series of responses aimed at restoring cellular energy
balance by switching off ATP-consuming, anabolic pathways, such
as fatty acid synthesis and protein synthesis and switching on ATP-
generating pathways such as fatty acid oxidation and glycolysis.
Biochemical analyses showed that while the total level of AMPK is
unchanged in xav, the level of activated AMPK (phospho-
AMPKa
Thr172) protein is significantly increased (Figure 3D, 3E).
This result suggests that there is a homeostatic regulation in xav
mutants, in response to alterations in metabolism. In addition,
measurement of ATP levels showed a ,45% reduction in xav
mutant compared to WT embryos (Figure 3F), despite a
compensatory increase of complex IV, complex V and activated,
p-AMPK protein levels. Together, these results suggest that the
etfdh mutation in xav results in metabolic reprogramming, which is
not restricted to and cannot fully compensate for the defect in the
fatty acid oxidation.
In order to gain more insight into the mitochondrial dysfunction
in xav and the underlying molecular mechanisms, we profiled the
expression of genes known to be involved in mitochondrial
function and biogenesis with qRT-PCR (Figure 3G). We found a
,30–40% reduction of mt-nd5 and ndufs1, two mitochondria
encoded genes that belong to complex I. Mutations of these genes
are associated with complex I deficiency and mitochondrial
encephalomyopathy, lactic acidosis, and stroke-like episodes
(MELAS), two disorders which have neurological manifesta-
tions[13,14,15]. The expression of pgc-1b, esrra and pparc, genes
involved in transcriptional regulation of energy metabolism, were
increased ,2.4, 1.5 and 2.8 fold, respectively. Interestingly,
expression of zebrafish uncoupling protein 4 (fucp4), which is proposed
to be responsible for uncoupling of respiration from ATP synthesis
and thus protect against reactive oxygen species (ROS) produc-
tion, showed a ,6 fold increase, while ucp2 expression remained
unchanged. The closest homologue of fucp4 in humans, UCP3, has
been reported to be upregulated in MADD patients[16]. These
results document mitochondrial dysfunction at the level of
alteration of gene expression in xav mutants as a result of etfdh
mutation.
Impairment of mitochondrial metabolism, including b-oxida-
tion, may result in greater oxidative stress[17], which increases
generation of ROS. The oxidative fluorescent dye dihydroroda-
mine-123 (DHR-123) was used to qualitatively address cellular
superoxide production. DHR-123 labeling in live embryos showed
higher cellular superoxide levels in xav mutants compared to WT,
especially in the nervous system, including in the spinal cord
(Figure 3H). We next assessed the expression profile of genes
known to be involved in the ROS pathway. qRT-PCR analyses
showed a 50% reduction of catalase transcripts and 5-fold increase
of glutathione reductase (Figure 3I), both of which are known to
function in ROS scavenging. We also found a 5 fold increase of
hspa9 (Figure 3I), mutation of which produces an increase in ROS
in blood cells[18]. These results further confirm that etfdh mutation
results in mitochondrial dysfunction and subsequent oxidative
stress in xav mutants. Moreover, the increased membrane potential
observed with a-ketoglutarate + malate in xav, as discussed above,
may also contribute to the increased ROS production. Mitochon-
drial ROS formation is favored by a high transmembrane
potential: increased membrane potential decreases electron flow
and decreased electron flow in turn increases the half-life of
partially reduced components of the electron transport chain,
thereby increasing the probability these carriers may donate an
electron to O2 to form superoxide[19,20].
Human MADD Fibroblast Cells Display Similar
Mitochondrial Dysfunction as xav Mutants
We next asked whether the mitochondrial abnormalities
observed in xav are similar to those in MADD patients. As
analyses of MADD patient tissues are rare, and postmortem tissues
are not available, we performed analyses on fibroblast cells from
Patient 1, and a control patient.
Fibroblasts from Patient 1 exhibited markedly increased
uncontrolled mitochondrial respiration as elicited by the uncou-
pler carbonyl cyanide m-chlorophenylhydrazone (CICCP) com-
pared to control fibroblasts (Figure 4A), resembling the increased
complex IV activity and complex V expression observed in xav.
The observation that uncoupler-stimulated respiration in fibro-
blasts from Patient 1 was so significantly above the basal
respiratory rate suggests that proton translocation through the
mitochondrial ATP synthase in situ limits state 3 oxygen
consumption, and therefore ATP synthesis, in these cells. The
addition of uncoupler relieves/removes any constraint on
respiration which may be imposed by proton movement through
the ATP synthase, thereby increasing respiration to a maximal
level. Basal ATP levels were slightly but significantly reduced in
Patient 1 fibroblasts (Figure 4B). These results suggest altered
respiratory capacity and compensation in MADD patients as in
xav mutants. Moreover, while electron transport chain is
compromised, cells in vitro are more readily able to maintain
ATP homeostasis than in vivo, either by upregulating reserve
respiratory capacity, by shifting to glycolysis (as discussed in the
following section) or by reducing dependence on fatty acids.
Gene expression profiling revealed that PGC-1b, PPARG,
ESRRa, UCP3 were all significantly increased in Patient 1
(Figure 4C), as in xav. Furthermore, the expression of ROS
related genes are also altered in Patient 1, as in xav, in particular
decreased catalase and increased glutathione reductase and HSPA9
(Figure 4C). These results extend our understanding of the extent
of mitochondrial dysfunction in human MADD, and show further
that this dysfunction is similar at the metabolic and gene
expression level in xav and MADD patients. Furthermore, this
indicates that the dysfunction is independent of the particular gene
Zebrafish Model of MADD
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demonstrate similar abnormalities in these studies.
MADD Fibroblasts and xav Mutants Exhibit Increased
Aerobic Glycolysis
During the course of measuring mitochondrial oxidative
responses, we noticed that there was also a significant increase in
the extracellular acidification rate (ECAR) in Patient 1 fibroblasts,
especially in the presence of an uncoupler (Figure 5A). ECAR
reflects changes in proton concentration and is used as readout of
lactate production as this dominates the acidification and is thus
used as a surrogate for glycolysis[21]. While the increase in ECAR
in Patient 1 fibroblasts suggested that aerobic glycolysis is increased,
we performed two additional analyses to further examine this
possibility. First, the amount of lactate secreted into the culture
medium was directly measured in Patient 1 fibroblasts. Basal lactate
production was increased by ,25%, consistent with increased
glycolysis(Figure 5B). Second, theexpression profile of genescritical
for glycolysis or in the glycolytic pathway was assessed using qRT-
PCR. mRNA for glycolytic enzymes enolase 1 (ENO1), phosphoglycerate
mutase 1 (PGAM1), phosphoglycerate kinase 1 (PGK1)a n dphosphofructo-
kinase (PFKM) were all significantly increased in MADD patients
(Figure 5C). These results suggest that aerobic glycolysis is increased
in fibroblasts from MADD patients.
To determine whether glycolysis is also elevated in xav mutants,
the amount of lactate was directly measured and was found to be
increased by ,2.4 fold in xav mutants compared to WT embryos at
,56 hpf (Figure 5D). Gene expression analyses by qRT-PCR
revealedsignificantchangesinexpressionofseveralglycolyticgenes.
mRNA for the glycolytic enzymes eno1, pgam1a, pgk1 and pfkma,a s
well as fructose-biphosphate aldolase C (aldoc) was significantly increased
(Figure 5E). mRNA for dihydrolipoamide S-acetyltransferase (dlat), that
belongs to the pyruvate dehydrogenase complex (PDH) which links
glycolysis to tricarboxylic acid (TCA) cycle, was significantly
decreased (Figure 5E). Together, these data suggest that in both
human MADD cells and xav mutants, the defect in fatty acid
oxidation compromises oxidative phosphorylation, leading to an
upregulation in aerobic glycolysis as an alternative energy source,
possibly as a consequence of AMPK activation, in an attempt to
compensate for this metabolic insuffiency. Furthermore, the
decreased expression in of dlat in xav will likely result in decreased
activity of PDH, in turn diverting pyruvate away from mitochon-
dria, decreasing flux through the Krebs cycle and thereby
decreasing delivery of reducing equivalents in the form of NADH
to the electron transport chain. Shunting of pyruvate away from
mitochondria would thus contribute to the conversion of glucose to
lactate and further exacerbate any underlying defects in the electron
transport chain by restricting oxidation of a very important
mitochondrial substrate, favoring a glycolytic phenotype.
xav Mutants Exhibit Increased Neural Proliferation
Many proliferating cells, including some cancer cells, utilize
aerobic glycolysis, which while an inefficient way to generate ATP
β α
Figure 4. Human MADD fibroblast cells display similar mitochondrial defects as xav mutants. A. Oxygen consumption was measured in intact
controlandMADDPatient1fibroblastsunderbasalconditions,followingtheadditionofthemitochondrialATPsynthaseinhibitoroligomycin(0.5 mg/ml),inthe
presence of the uncoupler CICCP (3 mM) to maximally stimulate respiration and following the addition of complex I inhibitor rotenone (100 nM) to assess
residual non-mitochondrial oxygenconsumption.A2-foldincreasewasobservedinPatient1fibroblasts comparedtocontrol, afteruncoupler CICCP treatment,
which measures the maximal uncontrolled mitochondrial respiratory capacity (N=3 experiments, 7–9 replicates of cells from passage 7–12; Student’stt e s t ,
*** p,0.001). B. Measurement of ATP levels showed a ca. 10% reduction in MADD Patient 1 fibroblast cells compared to control (N=14 replicates of cells from
passage 7–12; Student’s t test, * p,0.05). C. Gene expression assayed by qRT-PCR revealed that PGC-1b, PPARG, ESRRa, UCP3 were increased ,2, 4.6, 2 and 1.6
fold in Patient 1 compared to control. The expression of ROS related genes are also altered in Patient 1, with a ca. 20% decrease in catalase a n d4 . 7a n d5 . 7f o l d
increase in glutathione reductase and HSPA9 expression (N=3–7 replicates of cells from passage 7–12; Student’s t test, * p,0.05, ** p,0.01, *** p,0.001).
doi:10.1371/journal.pone.0008329.g004
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have the advantage of generating a number of biosynthetic
intermediates which can be used to incorporate nutrients into the
cell biomass, a phenomenon known as the Warburg effect[22].
Because a shift away from oxidative phosphorylation to an
increased dependence upon aerobic glycolysis may affect prolif-
eration, and because of the striking neural phenotypes observed in
xav mutants, including reduced neuropil staining, abnormal glial
patterning, reduced motor axon branching and neuromuscular
synaptogenesis, increased cell death and progressive paralysis
(Supplemental Results Text S1 and Figure S5, S6, S7, S8, S9), we
asked whether neural cell proliferation is increased in xav mutants
compared to WT embryos using BrdU incorporation.
The number of BrdU+ cells was significantly increased
throughout the nervous system, in particular in the spinal cord,
of xav mutants compared to WT embryos at 56–60 hpf (Figure 6A,
6B). While in ,56–60 hpf WT embryos, there are ,3 BrdU+ cells
in the spinal cord per hemisegment, there are ,24 in xav mutant
embryos at the same developmental stage, resulting in an
expansion of the proliferating cellular domain dorso-ventrally
and rostro-caudally (Figure 6A). The peri-ventricular location of
these BrdU+ cells suggests that they are likely to be neural
progenitor cells[23,24]. These observations suggest that neural cell
proliferation is increased in the nervous system of xav mutants.
Relationship between Increased Activation of the PPAR-ERK
Pathway and Increased Neural Proliferation in xav Mutants
In order to explore the mechanistic relationship between
metabolic dysfunction and increased neural proliferation in xav,
we focused on the PPARG-ERK pathway. PPARG is a known
regulator of the cell cycle and apoptosis, and is highly expressed in
many cells, including neurons and some human cancer cells[25].
High levels of PPARG expression have been reported in
embryonic mouse brain and neural progenitors, while very low
levels have been reported in adult mouse brain[26,27]. Recently,
PPARG has been shown to regulate neural proliferation in vitro,
through the activation of ERK and STAT3[28]. Because our
qRT-PCR analyses showed a dramatic increase in PPARG
expression in xav mutant embryos and MADD patient fibroblasts,
this pathway was further examined using Western blot and
immunostaining analyses.
Western blot analyses showed that PPARG protein levels were
elevated in xav, consistent with elevated mRNA expression
(Figure 6D). Western blot and immunostaining analyses were also
used to assess ERK activation using a phospho-ERK specific
antibody (dp-ERK)[29]. The amount of dp-ERK protein was
significantly increased, and dp-ERK immunoreactivity was
increased in the spinal cord, of xav compared to WT embryos at
,56–60 hpf (Figure 6A, 6D). BrdU labeling of dividing cells and
Figure 5. Increased aerobic glycolysis in MADD fibroblasts and xav mutants. A. ECAR was measured in intact control and MADD Patient 1
fibroblasts under basal conditions, following the addition of the mitochondrial inhibitor oligomycin (0.5 mg/ml), in the presence of the uncoupler
CICCP (3 mM) and following the addition of the complex I inhibitor rotenone (100 nM). A trend towards higher ECAR rate was seen under basal
conditions, and a significant 2-fold increase was observed after uncoupler CICCP treatment in Patient 1 fibroblasts compared to control. (N=3
experiments, 7–9 replicates of cells from passage 7–12; Student’s t test, * p,0.05). B. Lactate present in the culture medium showed a ,20% increase
in the basal lactate production in Patient 1 fibroblasts compared to control (N=2 experiments, 5–6 replicates of cells from passage 7–8; Student’s t
test, * p,0.05). C. qRT-PCR analyses of genes involved in glycolysis showed glycolytic enzymes enolase 1 (ENO1), phosphoglycerate mutase 1 (PGAM1),
phosphoglycerate kinase 1 (PGK1) and phosphofructokinase (PFKM), were increased by ,1.9, 2.7, 3.4 and 3.1 fold respectively in Patient 1 fibroblasts
compared to control (N=5 replicates of cells from passage 7–9; Student’s t test, * p,0.05, *** p,0.001). D. Lactate levels showed a ,2.4 fold increase
in xav mutants compared to WT embryos at ,56 hpf (N=7–9 replicates, 30–100 embryos each; Student’s t test, * p,0.05). E. qRT-PCR analyses of
gene expression revealed increased expression of glycolytic enzymes eno1, pgam1a, pgk1, pfkma, and fructose-biphosphate aldolase C (aldoc) by 2.8,
2, 1.9, 1.8 and 2.1 fold respectively, as well a ,20% decrease in dihydrolipoamide S-acetyltransferase (dlat), that belongs to the pyruvate
dehydrogenase complex, which links glycolysis to tricarboxylic acid (TCA) cycle, in xav mutants compared to WT embryos at ,56 hpf (N=3–7
replicates, 20 embryos each; Student’s t test, * p,0.05, ** p,0.01).
doi:10.1371/journal.pone.0008329.g005
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revealed a significant increase in the number of double positive
BrdU+/dp-ERK+ cells, from ,0i nW Tt o,8 per hemisegment
in xav mutant embryos at ,56–60 hpf (Figure 6A, 6C).
Furthermore, 45% of the BrdU+ cells were dp-ERK positive.
Western blot analyses were then used to assess the level of
activated STAT3 protein, using an antibody against phosphory-
lated STAT3 (phospho-STAT3
Tyr705)[30]. The amount of
phosphorylated STAT3 protein was significantly increased in xav
embryos (Figure 6D). These results suggest that the PPARG-ERK
pathway is dysfunctional in xav mutants, and is associated with
increased cell proliferation.
γ
γ
µµ
Figure 6. xav mutants exhibit increased neural cell proliferation as a result of increased glycolysis, due to perturbation of the
PPARG-ERK pathway. A. Whole mount embryos labeled with BrdU to mark cells undergoing proliferation. The number of BrdU+ cells was
significantly increased in the nervous system, especially in the spinal cord, in xav mutants compared to WT embryos at ,56–60 hpf. Increased dp-
ERK+ cells and BrdU+/dp-ERK+ double labeled cells in the spinal cord in xav mutants compared to WT embryos at ,56–60 hpf. B. In spinal cord
cross-sections from xav mutants and WT embryos at ,56–60 hpf, BrdU+ cells are distributed peri-ventricularly, suggesting that they are likely to be
neural progenitor cells. Dashed line outlines the spinal cord and indicates the midline. Scale bar=20 mm. C. Quantification of BrdU+ and dp-ERK+
cells at ,56–60 hpf. Per spinal cord hemisegment: BrdU+ cells WT 3.260.4, xav 2461.4; dp-ERK+ cells WT 2.660.3, xav 19.460.8; BrdU+/dp-ERK+ WT
0.260.2, xav 7.861.2. Percent of BrdU+ cells that are also dp-ERK+: WT 3.6%63.6%, xav 45%68% (N=4-19 embryos, .2 carrier pairs; Student’s t test,
*** p,0.001). D. Western blot analyses of pparc, dp-ERK and phospho-STAT3 expression showed dramatic increase in xav compared to WT embryos
at ,56–60 hpf (N=3 replicates, 30 embryos each; Student’s t test, * p,0.05). E. BrdU labeling of proliferating cells in whole mounts of spinal cord of
WT embryos, xav mutants, WT treated with 25 mm BADGE, xav mutants treated with 25 mm BADGE and WT treated with 10 mm Ciglitizone at ,56–
60 hpf. Embryos were raised in BADGE or Ciglitizone from 24 to 60 hpf. Per spinal hemisegment: BrdU+ cells WT 3.260.4, WT + BADGE 4.560.3, xav
2461.4, xav + BAGDE 10.660.9, WT + Ciglitizone 3662.5 (N=6–19 embryos, .3 carrier pairs; one-way ANOVA, followed by Bonferroni’s multiple
comparison test, *** p,0.001).
doi:10.1371/journal.pone.0008329.g006
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mechanistic relationship between the PPARG-ERK pathway and
the increased cell proliferation observed in xav mutant embryos.
We found that 25 mM of the PPARG antagonist 2,2-Bis[4-
(glycidyloxy)phenyl]propane, 4,49-isopropylidenediphenol diglyci-
dyl ether (BADGE), when applied from 24–60 hpf, significantly
reduced the number of BrdU+cells in the spinal cord of xav
mutants, from ,24 to ,10 cells per hemisegment (Figure 6E).
Furthermore, 10 mM of the PPARG agonist Ciglitizone, when
applied to WT embryos from 24–60 hpf, significantly increased
cell proliferation in the spinal cord, from ,3 to 36 cells per
hemisegment (Figure 6E). Moreover, we found that BADGE,
when applied from 24–60 hpf, significantly reduced the propor-
tion of xav mutants that were paralyzed at ,60 hpf, from 18% to
4%, and also delayed the onset of paralysis by ,12 hours
(Figure 6F; see also Supplemental Results Text S1).
Together, these data suggest that aberrant activation of the
PPARG-ERK pathway underlies, at least in part, the cell
proliferation and behavioral defects that are prominent in xav
mutants, linking metabolic and mitochondrial dysfunction with
defects in nervous system development, and possibly other organ
system development, in xav mutants and MADD patients.
Discussion
We report that the xav mutation causes a loss of ETFDH
function and defective electron transfer, and that both xav and
fibroblasts from a phenotypically severe MADD patient have
similar metabolic defects and mitochondrial dysfunction, including
altered energy metabolism, dysregulated ROS production and
altered expression of genes critical for mitochondrial function. xav
mutants and MADD fibroblasts exhibit increased aerobic
glycolysis, similar to the Warburg effect observed in cancer cells,
leading to excessive neural proliferation in xav, mediated by
upregulation of the PPARG-ERK pathway. xav mutants also
display motility defects culminating in paralysis, abnormal glial
patterning, reduced motor axon branching and neuromuscular
synapse number, but muscle fiber and neuromuscular synapse
function appear normal. While there is increased apoptosis
throughout the nervous system, many of these phenotypes are
independent of cell death, as they are not rescued when cell death
is blocked. Strikingly, a PPARG antagonist attenuates aberrant
neural proliferation and alleviates paralysis in xav, while PPARG
agonists increase neural proliferation in wild type embryos. This
work provides further insights into the relationship between
metabolism and neural development, specifically that mitochon-
drial dysfunction leads to an increase in aerobic glycolysis which
affects neurogenesis, at least in part through the PPARG-ERK
pathway.
While it is not surprising that mutations in ETF genes or
ETFDH would lead to impaired fatty acid, choline and amino acid
metabolism, it is interesting that a broader metabolic defect is also
present. Our finding that mitochondrial oxidative phosphorylation
stimulated by substrates other than fatty acids is also compro-
mised, and that there is a compensatory elevation of complex IV
activity, complex V expression and glycolysis further supports the
idea that there is crosstalk between bioenergetic and metabolic
pathways[31].
In most cancer cells and other rapidly proliferating cell
populations, ATP is produced primarily by aerobic glycolysis
followed by lactate fermentation, rather than by mitochondrial
oxidative phosphorylation as in normal, differentiated cells, a
phenomenon known as the Warburg effect. The Warburg effect
has been proposed as an adaptive strategy to facilitate the uptake
and incorporation of essential biosynthetic intermediates needed
for increasing cell biomass and proliferation[22]. Despite under-
standing that proliferating cells switch from oxidative phosphor-
ylation to aerobic glycolysis, the underlying triggers, effectors and
mediators of this switch remain elusive. We show using several
cellular and molecular assays that xav mutants and MADD
fibroblasts exhibit a similar switch characterized by enhanced
aerobic glycolysis accompanied by reduced mitochondrial oxygen
consumption, the consequence of which is increased cell
proliferation, in particular in the nervous system of xav mutants.
While the molecular basis of the metabolic pathology in MADD
can be explained by the malfunction of fatty acid, choline and
amino acid metabolism as a result of ETF or ETFDH mutation [5],
it remains unclear why individuals with MADD exhibit other
defects, especially neurological defects including cortex dysplasia,
encephalopathy and leukodystrophy[32,33,34,35]. In xav mutants,
the deficiency of fatty acid metabolism and oxidative phosphor-
ylation may force cells to augment glycolysis as an alternative
energy source for energy and biosynthetic intermediates to
preserve viability. This switch may alter the balance between cell
proliferation and differentiation, a major regulator of which is
PPARG signaling. In both xav mutants and MADD fibroblasts,
PPARG expression is increased at the mRNA and protein level,
and activation of downstream effectors such as ERK and STAT3
are also increased. We showed that PPARG elevation underlies, in
large part, the increase in cell proliferation in the nervous system
of xav mutants by antagonizing this pathway in xav and agonizing
this pathway in WT embryos. Under physiological conditions, the
PPARG pathway may act as a sensor of the balance between
oxidative phosphorylation and aerobic glycolysis, and shift the
balance between neural cell proliferation and differentiation
accordingly.
Using xav as a model for MADD, we have gained new insights
into the cellular and molecular mechanisms underlying this rare
but devastating human disorder. xav is the first animal model in
which the etfdh gene is affected and in which neural defects can be
demonstrated and studied. We have also identified the PPARG-
ERK pathway as potentially valuable for therapeutic intervention.
Understanding the relationship between metabolic and mitochon-
drial deficiencies and the mechanisms underlying the pathology of
MADD, in particular the neurological phenotypes, has been
hampered by the rarity of the disorder and thus analyses of
autopsy and other tissues has been limited[5]. It will be of
particular interest to assess neural cell proliferation and other
neural phenotypes in MADD patients as tissues become available.
The striking phenotypic similarity between xav and MADD patient
cells suggests that xav mutants will be a useful discovery tool to
guide future analyses in human MADD patients, and identify
avenues for therapeutic intervention.
Supporting Information
Text S1 Supplemental Results and Methods
Found at: doi:10.1371/journal.pone.0008329.s001 (0.10 MB
DOC)
Table S1 Primer sequences for new zebrafish simple sequence
repeat (SSR) markers.
Found at: doi:10.1371/journal.pone.0008329.s002 (0.03 MB
DOC)
Table S2 Primers for qRT-PCR analyses of gene expression in
xav and fibroblasts from human MADD patients.
Found at: doi:10.1371/journal.pone.0008329.s003 (0.08 MB
DOC)
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between genes in the xav interval and human chromosome 4. xav
linkage results suggest the sequence in and around BAC clone
DKEY-50I13 (accession no. CR846102.12) is misplaced on the
Ensembl Zv6 genome build.
Found at: doi:10.1371/journal.pone.0008329.s004 (0.46 MB EPS)
Figure S2 Nonsense mediated decay and nonsense mediated
alternative splicing of etfdh transcript in xav, and morpholino knock
down of etfdh. A. qRT-PCR showed that there is a significant,
,80% reduction of etfdh mRNA in xav, likely due to nonsense
mediated decay. N=3 pools of 20 embryos each for WT and xav;
Student’s t test, * p,0.0001. B. xav mutants showed nonsense
mediated alternative splicing. As a result of the mutation, which
resides in exon11, the exon10-exon13 junctions are mis-spliced in
mutants, resulting in transcripts that are predicted to encode
proteins lacking critical domains or truncated. Blue arrows
indicate primer location. These results suggest that the xav
mutation is likely to be loss of function. C. A splice-blocking
morpholino against intron2-exon3 (MOI2E3) was designed for
etfdh. D. Injection of 8 ng etfdh MOI2E3 in WT embryos, results
in .80% reduction of the normal transcript at 2 and 3 dpf,
producing a mis-spliced transcript that lacks exon3. Red arrow
indicates the MO location and blue arrows indicate primer
location.
Found at: doi:10.1371/journal.pone.0008329.s005 (0.44 MB EPS)
Figure S3 xav mutants display polycystic kidney like phenotypes.
Immunostaining of whole mount zebrafish embryos revealed that
the cilia in the pronephric ducts, as labeled by immunostaining
with anti-acetylated tubulin antibody, appear distended and
irregularly thickened, and contain gaps, in xav mutants compared
to WT embryos at ,60 hpf. Pronephric duct epithelial cells, as
labeled by immunostaining with the anti-NaK ATPase antibody
a6F, appear irregular in shape and showed aberrant clustering in
xav embryos. N=.10 xav and WT embryos for each immuno-
staining assessment. Scale bar=20 mm.
Found at: doi:10.1371/journal.pone.0008329.s006 (0.39 MB EPS)
Figure S4 xav mutants exhibit respiratory deficiency. A.
Polarographic traces showing O2 consumption by mitochondria
in WT and xav homogenates. Freshly prepared homogenates from
WT and xav embryos were incubated in an oxygen sensor
chamber, and O2 consumption (y axis) as a function of incubation
time (x axis) was recorded. In the upper panels, homogenates were
incubated with a-ketoglutarate + malate, and in the lower panels,
homogenates were incubated with fatty acid (C16 carnitine +
malate). Maximal rates of electron transfer were determined from
the rates of O2 consumption driven by ADP (0.2 mM) and
inorganic phosphate (state 3) and state 4 determined from the rate
of O2 consumption upon conversion of the ADP to ATP. N=.10
embryos from at least 2 carrier pairs for each metabolic assay. B.
At ,56 hpf, a higher level of F1-F0 ATPase (complex V) protein
was detected by immunostaining (red) in xav mutants (lower
panels) compared to WT embryos (upper panels). A higher
magnification view of the spinal cord is shown in the right most
panels. TUNEL staining (green) was performed simultaneously
and showed that there is increased cell death in the spinal cord in
xav and that complex V positive cells are also TUNEL positive in
xav.N = .10 embryos from at least 2 carrier pairs for each
immunostaining assay. Scale bar=100 mm.
Found at: doi:10.1371/journal.pone.0008329.s007 (0.89 MB EPS)
Figure S5 xav mutants exhibit neural and glial defects and cell
death. At 3 dpf, xav embryos exhibited increased cell death as
assayed by TUNEL staining (green), reduced neuropil as assayed
by SV2 staining (blue). Glia number and patterning as assayed by
GFAP staining (red) was aberrant throughout the nervous system.
Not only were glial processes irregular in shape, but clumps of
GFAP+cells were observed in several brain regions (white
arrowheads point to several examples). N.3 embryos, 1 carrier
pair. Scale bar=20 mm.
Found at: doi:10.1371/journal.pone.0008329.s008 (0.33 MB EPS)
Figure S6 xav mutants exhibit reduced motor axon branching
and neuromuscular synaptogenesis that are not caused by change
of motor neuron number or viability. A. SV2 (green) and AChR
(red) labeling showed that motor axon branching and neuromus-
cular synaptogenesis were reduced in xav mutants and etfdh
morphants compared to WT embryos, at 56 hpf and most
strikingly at 72 hpf. Scale bar=20 mm. B. Motor neuron number,
as assayed by in situ hybridization for islet-2, is similar between xav
mutants and WT embryos at 48 hpf. Scale bar=100 mm. C. No
substantial apoptosis was seen in the pool of motor neurons in xav
compared to WT at 48 hpf, as assayed by double staining for
TUNEL and Zn5, which labels secondary motor neurons. N.10
embryos, 3 carrier pairs. Scale bar=20 mm.
Found at: doi:10.1371/journal.pone.0008329.s009 (0.38 MB EPS)
Figure S7 xav mutants display electrophysiological properties in
the muscle, comparable to WT. A–C. Miniature excitatory
postsynaptic current (mEPC) recordings from fast muscles showed
a significant reduction in the mEPC rise time (WT
0.12260.007 ms, xav 0.09660.002 ms, N=6, Student’s t test,
*p ,0.05) and the frequency (WT 0.3660.07 Hz, xav
0.1060.05 Hz, N=6; Student’s t test, * p,0.05), but no statistical
difference in terms of amplitude and exponential decay time.
N=6–8 embryos, 2 carrier pairs. D. Muscle fibers from xav
embryos fire action potentials after exogenous stimulation,
comparable in amplitude and shape to action potentials recorded
from muscle fibers from WT embryos. There is no significant
difference in terms of action potential amplitude, threshold or half
width. N=5 embryos, 2 carrier pairs.
Found at: doi:10.1371/journal.pone.0008329.s010 (4.62 MB EPS)
Figure S8 xav mutants exhibit aberrant mitochondria distribu-
tion in motor neurons. A–B. Mito-GFP was expressed in motor
neurons and branching and synapse formation followed over time.
In WT embryos at ,56 hpf, mitochondria are distributed along
the entire axon. Mitochondria are continuously added over time,
increasing both in number and density. In contrast, in xav mutants,
while the number and distribution of mitochondria clusters along
the axon are comparable to WT embryos at ,56 hpf, the
continuous addition of mitochondria is absent, resulting in a
decrease of mitochondria cluster density by 3 dpf. N=9–10
embryos, 3–4 carrier pairs. Scale bar=20 mm.
Found at: doi:10.1371/journal.pone.0008329.s011 (0.51 MB EPS)
Figure S9 xav mutants exhibit cell death throughout the nervous
system that is rescued by p53 morpholino knockdown and does
not account for the motor axon branching, neuromuscular synapse
or motility defects. A. xav mutants exhibit widespread cell death in
the peripheral and central nervous system. There was a dramatic
increase in TUNEL+cells in xav mutants compared to WT
embryos at ,56–72 hpf, particularly in the retina and spinal cord.
B. At 56 hpf, cell death was blocked using a morpholino against
p53. However, blocking cell death did not block the reduction of
axon branching and synaptogenesis phenotypes that are present in
xav mutants. N.6 embryos, 2 carrier pairs. Scale bar=100 mm.
Found at: doi:10.1371/journal.pone.0008329.s012 (0.39 MB EPS)
Video S1 Spontaneous movements and motility in wild type
zebrafish embryos at 48 hpf. The motility of wild type and xav
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PLoS ONE | www.plosone.org 11 December 2009 | Volume 4 | Issue 12 | e8329mutant embryos were examined using high-speed video micros-
copy at 48 hpf. Wild type embryos spend most of the time staying
still when not stimulated, and exhibit quick, darting movements
when they swim.
Found at: doi:10.1371/journal.pone.0008329.s013 (3.98 MB AVI)
Video S2 xav mutants exhibit increased spontaneous movement
but with reduced motility at 48 hpf. The motility of wild type and
xav mutant embryos were examined using high-speed video
microscopy at 48 hpf. xav mutants show increased spontaneous
twitching when not stimulated, and exhibit reduced motility when
they swim, often exhibiting spasmodic like movements.
Found at: doi:10.1371/journal.pone.0008329.s014 (4.91 MB AVI)
Acknowledgments
We thank Dr. William J. Rhead for providing MADD patient fibroblasts,
Dr. Carsten Bonnemann for providing control patient fibroblasts, Drs.
Marnie Halpern and Bill Saxton for providing the mito-GFP construct,
Drs. Michael Granato and Dirk Meyer for providing the hb9 construct,
Drs. S. Nona and J. Scholes for providing the anti-GFAP antibody, Dr.
Ethan Hughes for assisting with quantification of neuromuscular synapses,
Dr. Ang Li for assistance with qRT-PCR analyses, Dr. Kevin Bittman for
assistance with the analyses using the XF24 instrumentation, Ms. Amy
Kugath for technical assistance, in particular with zebrafish husbandry,
and members of the Balice-Gordon lab for helpful discussions.
Author Contributions
Conceived and designed the experiments: YS RJBG. Performed the
experiments: YS MAS CTW CC PCS JAP SG MOS GW RGG DA MJB.
Analyzed the data: YS RJBG. Wrote the paper: YS RJBG.
References
1. Knott AB, Perkins G, Schwarzenbacher R, Bossy-Wetzel E (2008) Mitochon-
drial fragmentation in neurodegeneration. Nat Rev Neurosci 9: 505–518.
2. Mattson MP, Gleichmann M, Cheng A (2008) Mitochondria in neuroplasticity
and neurological disorders. Neuron 60: 748–766.
3. Erecinska M, Cherian S, Silver IA (2004) Energy metabolism in mammalian
brain during development. Prog Neurobiol 73: 397–445.
4. Wallace DC (2005) A mitochondrial paradigm of metabolic and degenerative
diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet
39: 359–407.
5. Frerman FE, Goodman SI (2001) Defects of electron transfer flavoprotein and
electron transfer flavoprotein ubiquinone oxidoreductase: glutaric acidemia type
II. In: Scriver CRBA, Sly WS, Valle D, eds. The metabolic and molecular bases
of inherited diseases. New York: McGraw-Hill. pp 2357–2365.
6. Ruzicka FJ, Beinert H (1977) A new iron-sulfur flavoprotein of the respiratory
chain. A component of the fatty acid beta oxidation pathway. J Biol Chem 252:
8440–8445.
7. McKean MC, Beckmann JD, Frerman FE (1983) Subunit structure of electron
transfer flavoprotein. J Biol Chem 258: 1866–1870.
8. Rinaldo P, Matern D, Bennett MJ (2002) Fatty acid oxidation disorders. Annu
Rev Physiol 64: 477–502.
9. Van Hove JL, Grunewald S, Jaeken J, Demaerel P, Declercq PE, et al. (2003)
D,L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase defi-
ciency (MADD). Lancet 361: 1433–1435.
10. Bonham JR, Tanner MS, Pollitt RJ, Robertson L, Pourfarzam M, et al. (1999)
Oral sodium 3-hydroxybutyrate, a novel adjunct to treatment for multiple acyl-
CoA dehydrogenase deficiency. J Inher Metab Dis 22: 101–119.
11. Panzer JA, Gibbs SM, Dosch R, Wagner D, Mullins MC, et al. (2005)
Neuromuscular synaptogenesis in wild-type and mutant zebrafish. Dev Biol 285:
340–357.
12. Hentze MW, Kulozik AE (1999) A perfect message: RNA surveillance and
nonsense-mediated decay. Cell 96: 307–310.
13. Benit P, Chretien D, Kadhom N, de Lonlay-Debeney P, Cormier-Daire V, et al.
(2001) Large-scale deletion and point mutations of the nuclear NDUFV1 and
NDUFS1 genes in mitochondrial complex I deficiency. Am J Hum Genet 68:
1344–1352.
14. Loeffen JL, Smeitink JA, Trijbels JM, Janssen AJ, Triepels RH, et al. (2000)
Isolated complex I deficiency in children: clinical, biochemical and genetic
aspects. Hum Mutat 15: 123–134.
15. Triepels RH, Van Den Heuvel LP, Trijbels JM, Smeitink JA (2001) Respiratory
chain complex I deficiency. Am J Med Genet 106: 37–45.
16. Russell AP, Schrauwen P, Somm E, Gastaldi G, Hesselink MK, et al. (2003)
Decreased fatty acid beta-oxidation in riboflavin-responsive, multiple acylcoen-
zyme A dehydrogenase-deficient patients is associated with an increase in
uncoupling protein-3. J Clin Endocrinol Metab 88: 5921–5926.
17. Wallace DC (1999) Mitochondrial diseases in man and mouse. Science 283:
1482–1488.
18. Craven SE, French D, Ye W, de Sauvage F, Rosenthal A (2005) Loss of Hspa9b
in zebrafish recapitulates the ineffective hematopoiesis of the myelodysplastic
syndrome. Blood 105: 3528–3534.
19. Murphy MP (2009) How mitochondria produce reactive oxygen species.
Biochem J 417: 1–13.
20. Adam-Vizi V, Chinopoulos C (2006) Bioenergetics and the formation of
mitochondrial reactive oxygen species. Trends Pharmacol Sci 27: 639–645.
21. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, et al. (2006)
Bile acids induce energy expenditure by promoting intracellular thyroid
hormone activation. Nature 439: 484–489.
22. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the
Warburg effect: the metabolic requirements of cell proliferation. Science 324:
1029–1033.
23. Mueller T, Wullimann MF (2002) BrdU-, neuroD (nrd)- and Hu-studies reveal
unusual non-ventricular neurogenesis in the postembryonic zebrafish forebrain.
Mech Dev 117: 123–135.
24. Mueller T, Wullimann MF (2003) Anatomy of neurogenesis in the early
zebrafish brain. Brain Res Dev Brain Res 140: 137–155.
25. Fajas L, Debril MB, Auwerx J (2001) PPAR gamma: an essential role in
metabolic control. Nutr Metab Cardiovasc Dis 11: 64–69.
26. Braissant O, Wahli W (1998) Differential expression of peroxisome proliferator-
activated receptor-alpha, -beta, and -gamma during rat embryonic development.
Endocrinology 139: 2748–2754.
27. Moreno S, Farioli-Vecchioli S, Ceru MP (2004) Immunolocalization of
peroxisome proliferator-activated receptors and retinoid X receptors in the
adult rat CNS. Neuroscience 123: 131–145.
28. Wada K, Nakajima A, Katayama K, Kudo C, Shibuya A, et al. (2006)
Peroxisome proliferator-activated receptor gamma-mediated regulation of
neural stem cell proliferation and differentiation. J Biol Chem 281:
12673–12681.
29. Neumann CJ, Nuesslein-Volhard C (2000) Patterning of the zebrafish retina by a
wave of sonic hedgehog activity. Science 289: 2137–2139.
30. Yamashita S, Miyagi C, Carmany-Rampey A, Shimizu T, Fujii R, et al. (2002)
Stat3 Controls Cell Movements during Zebrafish Gastrulation. Dev Cell 2:
363–375.
31. Brown GC (1992) Control of respiration and ATP synthesis in mammalian
mitochondria and cells. Biochem J 284 ( Pt 1): 1–13.
32. Bohm N, Uy J, Kiessling M, Lehnert W (1982) Multiple acyl-CoA
dehydrogenation deficiency (glutaric aciduria type II), congenital polycystic
kidneys, and symmetric warty dysplasia of the cerebral cortex in two newborn
brothers. II. Morphology and pathogenesis. Eur J Pediatr 139: 60–65.
33. Shevell MI, Didomenicantonio G, Sylvain M, Arnold DL, O’Gorman AM, et al.
(1995) Glutaric acidemia type II: neuroimaging and spectroscopy evidence for
developmental encephalomyopathy. Pediatr Neurol 12: 350–353.
34. Takanashi J, Fujii K, Sugita K, Kohno Y (1999) Neuroradiologic findings in
glutaric aciduria type II. Pediatr Neurol 20: 142–145.
35. Stockler S, Radner H, Karpf EF, Hauer A, Ebner F (1994) Symmetric
hypoplasia of the temporal cerebral lobes in an infant with glutaric aciduria type
II (multiple acyl-coenzyme A dehydrogenase deficiency). J Pediatr 124: 601–604.
36. Schiff M, Froissart R, Olsen RK, Acquaviva C, Vianey-Saban C (2006) Electron
transfer flavoprotein deficiency: functional and molecular aspects. Mol Genet
Metab 88: 153–158.
37. Shen JJ, Matern D, Millington DS, Hillman S, Feezor MD, et al. (2000)
Acylcarnitines in fibroblasts of patients with long-chain 3-hydroxyacyl-CoA
dehydrogenase deficiency and other fatty acid oxidation disorders. J Inherit
Metab Dis 23: 27–44.
38. Bennett MJ, Ragni MC, Hood I, Hale DE (1992) Comparison of post-mortem
urinary and vitreous humour organic acids. Ann Clin Biochem 29(Pt 5):
541–545.
39. Zannino DA, Appel B (2009) Olig2+precursors produce abducens motor
neurons and oligodendrocytes in the zebrafish hindbrain. J Neurosci 29:
2322–2333.
40. Nam DH, Ramachandran S, Song DK, Kwon KY, Jeon DS, et al. (2007)
Growth inhibition and apoptosis induced in human leiomyoma cells by
treatment with the PPAR gamma ligand ciglitizone. Mol Hum Reprod 13:
829–836.
Zebrafish Model of MADD
PLoS ONE | www.plosone.org 12 December 2009 | Volume 4 | Issue 12 | e8329